Agenus Data Suggests Biomarker-Driven Immunotherapy Stratification
Event summary
- Agenus presented biomarker data from its Phase 1b C-800-01 trial evaluating botensilimab (BOT) and balstilimab (BAL).
- The data suggest survival with BOT+BAL is linked to a balance of systemic inflammation and tumor immune activity.
- The combination demonstrated clinical benefit even with low levels of immune infiltration, a threshold typically insufficient for conventional checkpoint inhibitors.
- The study included 341 efficacy-evaluable patients with advanced cancers, achieving a 17% objective response rate and 38% 24-month overall survival rate.
- Integrated biomarkers improved overall survival stratification in microsatellite-stable metastatic colorectal cancer (MSS mCRC), a historically resistant population.
The big picture
Agenus’s findings challenge the reliance on traditional biomarkers like PD-L1 and tumor mutational burden in MSS mCRC, a significant unmet need in immuno-oncology. The ability to identify patient subgroups likely to respond to immunotherapy, even in ‘cold’ tumors, could expand the addressable market for checkpoint inhibitors and potentially lead to more targeted and effective treatment regimens. This data highlights a shift towards more nuanced, biologically-grounded patient selection in cancer treatment.
What we're watching
- Clinical Validation
- Whether the observed survival stratification in MSS mCRC can be consistently replicated in larger, randomized trials will be critical to validating the biomarker approach.
- Regulatory Pathway
- The FDA’s acceptance of these novel biomarkers for accelerated approval or companion diagnostics will influence the commercial viability of BOT+BAL.
- Competitive Landscape
- The pace at which other immuno-oncology companies integrate similar biomarker strategies into their development programs will determine Agenus’s competitive advantage.
Related topics